23results about How to "Lower titer" patented technology

The invention belongs to the technical field of biology, and particularly relates to a 3D protein mutated O-type foot-and-mouth disease recombinant virus strain as well as construction and application thereof. The 403th methionine of the O-type foot and mouth disease virus 3D protein is mutated into alanine, the recombinant virus strain rFMDV-M403A with the mutated O-type foot and mouth disease virus 3D protein is successfully constructed and saved by using a reverse genetic technology, and amino acid of the recombinant virus strain can be stably mutated in a passage process; the growth speed of the mutant strain is slower than that of a wild strain, and the virus titer is remarkably reduced; in an individual experiment, neonatal mouse infection shows that the mutant strain can improve the survival rate of neonatal mice, and the virus load and tissue lesion in the liver are remarkably reduced. The attenuated foot-and-mouth disease recombinant virus strain provided by the invention provides important significance for deep understanding of a foot-and-mouth disease virus pathogenic mechanism and a prevention and control strategy, and also provides an important theoretical basis for further development of a foot-and-mouth disease genetic engineering vaccine.

The invention belongs to the technical field of indication viruses, and particularly relates to a composition and application thereof in inhibition of retrovirus inactivation. The composition provided by the invention comprises 15 mM of glycine betaine and 50 mM of fructose. The fructose can increase the half-life period of the retrovirus and the cell specific productivity, and the glycine betaine can neutralize the negative effect of the high osmotic pressure environment on the cell growth. The glycine betaine and the fructose are compounded according to a certain proportion, so that the stability of the retrovirus can be improved, the inactivation of the retrovirus can be inhibited, the inactivation rate of the retrovirus can be reduced, the specific productivity of cells can be improved, the half-life period of the virus can be prolonged, the retrovirus stock solution with high stability and long half-life period can be obtained, and the time and the cost can be reduced; therefore, the safety and effectiveness of retrovirus production are improved.

The invention discloses a grease composition for resisting porcine envelope virus infection and application of the grease composition. The grease composition comprises at least two of glyceryl monovalerate, glyceryl monolinoleate and glyceryl monomyristate. The grease composition can also comprise absolute ethyl alcohol, propylene glycol, dimethyl sulfoxide, edible oil, lactose in Tween 80, mannitol, soluble starch, water and other auxiliary materials, and is used for preparing a grease composition preparation. The grease composition can inhibit envelop viruses in a multi-way and multi-layer mode, and the antiviral effect is improved. By adding the grease composition into pig feed, not only can the antiviral capability be improved, but also inflammatory response caused by pathogenic infection can be reduced through the anti-inflammatory and immune regulation effects of the grease composition, and the infection of swine envelope viral diarrhea can be effectively prevented and treated, so that the incidence rate of the swine envelope viral diarrhea and the death rate of diseased pigs are reduced. The grease composition can be used for preparing a medicine or a feed additive for treating and preventing swine envelope viral diarrhea.

The invention discloses xanthomonas citri subsp.citri phage and application thereof, and relates to the technical field of biology. The xanthomonas citrus subspecies phage is preserved in the China Center for Type Culture Collection on July 4, 2024, the preservation address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: M 20241486. The xanthomonas citrus subsp.citri bacteriophage can specifically inactivate the xanthomonas citrus subsp.citri, mass proliferation can be completed only with a small amount of initial bacteriophage, and a high-quality bacteriophage strain source is provided for industrial production of bacteriophage bactericides; technicists in the field can prepare various products applied to the aspects of detection, disinfection, plant protection and the like from the xanthomonas citrus subsp.citri phage provided by the invention according to records and common knowledge in the field by technicians in the field, and the products are industrially applied to the xanthomonas citrus subsp.citri phage.

The present invention relates to a composition for preventing and treating viral infection of the family of African swine fever viruses, in particular, a composition for treating, inhibiting and / or preventing viral infection of the family of African swine fever viruses (Asfaraviridae), preferably African swine fever virus, characterized in that the composition comprises one or more medium-chain fatty acids (MCFAs) and / or derivatives thereof.

The invention discloses an application of Z-ITED-FMK in preparation of a medicine for treating acne vulgaris, the Z-ITED-FMK can relieve auricle skin lesion of a mouse acne model, reduce auricle skin thickness, improve inflammatory response and reduce C.acnes titer, the Z-ITED-FMK has a treatment effect on AV, and the Z-ITED-FMK inhibits the inflammatory response of acne local skin and reduces the titer of C.acnes in the skin.

The invention relates to a Nile red derivative with photodynamic-photothermal performance as well as preparation and application thereof, two Nile red derivatives (TPACN and TPAOMCN) are elaborately designed and synthesized, and the structural formula is as follows: # imgabs0. The Nile red derivative disclosed by the invention can generate a large amount of active oxygen and efficient photothermal conversion under the irradiation of 660nm laser; a strong photodynamic-photothermal treatment effect is shown, multi-drug-resistant bacterium infection can be resisted to promote wound repair, and propagation of monkey pox viruses can be blocked. The TPAOMCN NFs provided by the invention can effectively remove drug-resistant bacteria in mouse wounds under laser irradiation, regulate inflammatory response and promote healing of infected wounds. In simulation of characteristic impetigo of monkey pox, after TPAOMCN NFs and laser treatment, virus titer in lesion is significantly reduced, infected lesion tissue is rapidly repaired, transmission of viruses to healthy mice is effectively blocked, and the TPAOMCN NFs has a huge application prospect.

The present invention provides a package body in which a pharmaceutical composition containing a glycolytic enzyme is stored in a container, and the package body can suppress the reduction of the potency caused by a small amount of enzyme. The package body comprises a pharmaceutical composition and a container, wherein the pharmaceutical composition is a lyophilized preparation containing a glycolytic enzyme as an active ingredient, and the container stores the pharmaceutical composition, and the inner surface of the container has at least one material selected from fine ceramics, silicone resins, and fluororesins.

The application relates to the technical field of medicines, in particular to application of an artemisinin compound in preparation of a medicine for treating and / or preventing NMOSD and a medicine composition. The application relates to application of an artemisinin compound in preparation of a medicine for treating and / or preventing NMOSD. The application provides a new medical use of an artemisinin compound, that is, application of artemisinin and derivatives thereof in preparation of a medicine for treating, relieving and preventing NMOSD, fills the above technical gap, provides a new treatment option for patients with NMOSD who are not sensitive to existing treatment or are not tolerant to the existing treatment, and makes up for the deficiency of the existing treatment. Specifically, the artemisinin compound can treat the core pathogenic link of NMOSD, realize the double effects of rapidly controlling inflammation in the acute stage and effectively preventing recurrence in the remission stage, reverses part of the nerve damage, and improves the nerve function of the patient.

This invention discloses a high-density phage culture method for *R. anatidae*, belonging to the technical field of high-density phage culture of *R. anatidae*. First, a standard strain of prevalent *R. anatidae* serotype is selected as the host bacterium. After activation, it is inoculated into an optimized culture medium supplemented with divalent cations. When the host bacterium is in the logarithmic growth phase, it is pre-amplified by inoculating the original phage lysate at a low multiplicity of infection, and high-lytic-activity phage strains are screened. Then, the screened phages are inoculated into an expansion culture system. During the culture process, nutrients are dynamically supplemented to maintain the activity of the host bacterium. After complete lysis of the host bacterium, a specific nuclease is added to the culture system to digest the free nucleic acid. The phage prepared by this invention has a high titer and can be directly used in formulation production without additional concentration. The culture system has low free nucleic acid residue, the phage loss rate during purification is low, and the obtained phage lysis spectrum covers a wide range.

The invention discloses miR-184 and application of the miR-184 in regulating and controlling the reproduction of female diaphorina citri. The nucleotide sequence of the micromolecule miR-184 provided by the invention is shown as SEQ ID NO.4, and the micromolecule miR-184 is highly expressed in the ovary of the female diaphorina citri. By feeding the miR-184 agonist, the egg laying amount of the diaphorina citri is obviously reduced, the development of the ovary is inhibited, the titer of the Candidatus Liberibacter asiaticum in the ovary is obviously reduced, and the miR-184 agonist has a good application prospect in the aspects of regulating and controlling the reproduction of female diaphorina citri, preventing and treating the female diaphorina citri, preventing the Candidatus Liberibacter asiaticum and the like.

This invention discloses the application of bufotoxin lactones in the preparation of anti-IHNV products, belonging to the field of biomedical technology. This invention is the first to discover and confirm that four bufotalin-based drugs (bufotalin, bufotalin ester, bufotalin, and bufotalin) have significant anti-IHNV effects: their IC50 values ​​against IHNV in vitro range from 0.0879 to 0.1809 μM, with selectivity indices all greater than 110. After 48 hours of treatment, they can reduce viral RNA expression by 110 to 173 times and viral titer by 4.36 to 5.15 lg; they also show broad-spectrum inhibitory effects against different genotypes of IHNV, such as LN-15, QH-17, and Blk94; in a rainbow trout in vivo model, after administration of a 0.5 mg / kg dose, the cumulative mortality rate decreased from 95% in the control group to 13.3% to 21.7%, with the highest relative protection rate reaching 85.96% (bufotalin), indicating that these compounds have highly efficient, broad-spectrum, and low-toxicity anti-IHNV activity and have excellent application prospects.

The present application relates to the fields of biotechnology and agricultural fishery, and discloses application of curcumin in preparation of an inhibitor of CyHV-2, and finds that curcumin can effectively inhibit the infection and replication of CyHV-2 virus in GiCF cells.The present application first applies curcumin to the prevention and treatment of CyHV-2 infection, thereby providing a new treatment scheme for CyHV-2 virus.Curcumin can effectively reduce the copy number of CyHV-2 virus, and curcumin can be used to prepare a drug for preventing and treating CyHV-2 infection, and a drug for treating viral hematopoietic organ necrosis in fish.

The present disclosure provides, inter alia, molecules comprising a binding domain that specifically binds to a target antibody and at least one modified Fc domain. The present disclosure also provides methods and compositions that allow for selective depletion and / or neutralization of pathogenic antibodies.

The invention relates to the technical field of microorganisms. The invention discloses a method for improving the titer of clostridium perfringens bacteriophage, which is characterized by comprising the following steps: S1, seed activation; s2, seed amplification; s3, expanded production of a fermentation tank: inoculating the host bacteria solution prepared in the step S2 into a fermentation medium, carrying out anaerobic culture for 0-3 hours at the temperature of 40-45 DEG C and the rotating speed of 10-30 rpm, then inoculating the bacteriophage proliferation liquid prepared in the step S2, carrying out anaerobic condition culture for 0.5-2 hours at the temperature of 35-40 DEG C and the rotating speed of 40-60 rpm, then raising the temperature to 40-45 DEG C and the rotating speed of 10-20 rpm, maintaining the tank pressure to 0.5-1.0 MPa, and carrying out fermentation for 2-3 hours at the temperature of 35-40 DEG C and the rotating speed of 40-60 rpm. Performing anaerobic culture for 4-6 hours, ending fermentation, and regulating the pH value on line. The invention also provides a bacteriophage product. According to the method for improving the titer of the clostridium perfringens phage provided by the invention, by improving the problem of pH drop in the production process, the production efficiency is improved, the stability of the clostridium perfringens phage in the finished product fermentation liquor is improved, and the storage period of the clostridium perfringens phage product in a normal-temperature environment is prolonged.

The invention discloses dihydropyrimidine (thio) ketone as shown in a general formula I or pharmaceutically acceptable salt thereof, and preparation and antiviral application of the dihydropyrimidine (thio) ketone or the pharmaceutically acceptable salt thereof. The compound has the effects of inhibiting PEDV virus replication and reducing virus titer, is used for preventing and treating PED in the pig breeding industry, and reduces the incidence rate and case fatality rate of PED. # imgabs0 #

The present application relates to the field of biological medicine, and particularly relates to a preparation for resisting African swine fever virus and application thereof.The preparation is obtained by carbonizing kaempferol in an alkaline environment;the particle size of the kaempferol carbon dots is 1nm-20nm;and the solubility of the kaempferol carbon dots in water is 0.1mg / mL-0.5mg / mL.The kaempferol carbon dots obtained by a solvothermal method have significantly improved water solubility and biocompatibility, reduced cytotoxicity, and are more suitable for use in a drug delivery system.The kaempferol carbon dots have a significant inhibitory effect on African swine fever virus, can reduce virus titer and reduce virus protein expression.The kaempferol carbon dots can inhibit the TLR4 signaling pathway, reduce the production of inflammatory cytokines, and remove active oxygen through SOD-like activity, thereby playing an antiviral role.

The present invention relates to the field of nanomaterials, and in particular to a metal ion-doped mRNA delivery platform and a preparation method thereof. The method comprises mixing mRNA with divalent manganese ions and forming nuclei to obtain core particles; and then encapsulating the core particles with phospholipid molecules. The present invention utilizes the interaction between divalent manganese ions and mRNA to enrich the two into nuclei, and a large amount of mRNA can be encapsulated inside using a small dose of phospholipids. The reaction process is simple and efficient, and the conditions are mild. It not only reduces the amount of phospholipids, reduces the risk of side effects represented by inflammatory reactions, reduces the production of anti-drug antibodies, but also can enhance the in vivo immune effect with the help of the immune adjuvant effect of manganese ions. When using the same phospholipid dosage, the present invention can deliver a higher content of mRNA than commercial LNP products, achieve stronger in vivo expression and functional effects, and provide a new platform tool for building a safer and more effective mRNA delivery system.

Provided is a package in which a pharmaceutical composition containing a glycolytic enzyme is accommodated in a container, said package being capable of suppressing a decrease in titer due to a small amount of enzyme. The packaging body contains a pharmaceutical composition and a container, the pharmaceutical composition is a lyophilized preparation containing a glycolytic enzyme as an active ingredient, the container contains the pharmaceutical composition, and the inner surface of the container is provided with at least one material selected from the group consisting of fine ceramics, silicone resins, and fluororesins.

The application discloses a kind of silkworm nuclear polyhedrosis virus bro-b gene deletion recombination virus and its construction and application.The recombination virus includes bro-b deletion virus and bro-b backfill virus;Wherein deletion virus is obtained by replacing bro-b gene with marker gene by Red homologous recombination, and backfill virus is obtained by introducing bro-b gene into deletion virus again.Experiments prove that: bro-b deletion significantly inhibits virus genome replication, early / late / very late gene transcription and virus proliferation, reduces virus titer and GP64 expression, improves cell viability, and bro-b protein and LEF-3, LEF-6 exist direct interaction.The application discloses that bro-b affects virus life cycle by regulating LEF-3 / LEF-6 for the first time, provides new target and matching virus tool for anti-BmNPV, and can be used for antiviral drug screening, silkworm disease-resistant breeding and baculovirus attenuated vector modification.

This invention relates to a method and application of the inhibitor EHop-016 for inhibiting porcine epidemic diarrhea virus (PEDV) infection in vitro. EHop-016 can be used to prepare antiviral drugs for inhibiting PEDV infection. In this invention, during the in vitro infection of African green monkey kidney cells (Vero) with PEDV, the addition of 4 μmol / L EHop-016 significantly reduced the viral load, protein expression level, RNA content, and viral titer of PEDV in the EHop-016-treated group compared to the control group without EHop-016, indicating that this inhibitor can be used to inhibit porcine epidemic diarrhea virus infection in vitro.

The invention relates to the technical field of microorganisms, and provides a vibrio alginolyticus phage and application thereof in order to screen and accumulate a phage with a good lysis effect, the latin classification name of the vibrio alginolyticus phage is Vibrio alginolyticus phage, the vibrio alginolyticus phage is named as GYN01, the vibrio alginolyticus phage is preserved in the China General Microbiological Culture Collection Center, the preservation number is CGMCC No.46683, and the vibrio alginolyticus phage is named as GYN01. The invention relates to an icosahedron-shaped tail sheath, which has a typical tadpole-shaped composite symmetrical structure, comprises an icosahedron head part and a retractable tail sheath, a tail plate visible at the tail end of the tail part, a non-retractable tail part and a hollow tail tube visible in the center of the tail sheath, has good temperature stability and a wider acid-base tolerance range, and is sensitive to ultraviolet rays; the compound has good cracking capacity and killing effect on pathogenic vibrio alginolyticus, is good in safety and environment-friendly, and can be used for preventing and treating vibrio alginolyticus diseases in the aquaculture process.

The invention belongs to the technical field of antiviral drugs, and particularly relates to application of astaxanthin in preparation of antiviral products. The virus comprises a DNA virus, a positive-sense single-chain RNA virus and a single-strand negative-chain RNA virus. In-vitro and in-vivo experiments prove that the astaxanthin can inhibit virus adsorption and internalization and relieve damage of viruses to cell membrane structures and functions, the astaxanthin can inhibit virus invasion and directly reduce virus titer in animal bodies, the research result of the invention expands the efficacy range of the astaxanthin, and the astaxanthin can be used for preparing the medicine for treating animal diseases. The astaxanthin is proved to be capable of preventing and treating infection and diseases caused by viruses for the first time.